Business Context and Reporting Period
Coya Therapeutics, Inc. (COYA), a Delaware corporation, filed this Form 8-K on January 8, 2026. The filing reports on an investigator-initiated proof of concept open-label study regarding a combination treatment for Frontotemporal Dementia (FTD).
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on clinical trial results.
Material Changes and Clinical Results
The Company announced positive results from a 6-month study involving 9 patients with FTD. The treatment regimen consisted of subcutaneously administered CTLA4-Ig and a 5-day course of low-dose IL-2 every four weeks for 22 weeks.
- Safety and Feasibility: No serious adverse events were observed. The most common adverse event was mild erythema at the injection site (33.3% of individuals), which recovered spontaneously.
- Immunological Response: Treg suppressive function and Treg percentage were significantly increased as early as 2 weeks post-dosing and remained elevated through week 22. CD25 and FOXP3 mean fluorescence intensity (MFI) also showed significant increases.
- Cognitive Stability:
- MOCA Scores: Remained stable (Baseline: 13.5; Week 22: 14), suggesting no decline in cognitive function.
- CDR-FTLD Scores: Did not significantly change (Baseline: 4.8; Week 22: 5.5), suggesting stability in cognitive and functional status.
Outlook, Risks, and Management Commentary
The study was led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute and funded by The Peggy and Gary Edwards Endowment Fund. Management highlights the enhanced Treg numbers and function alongside cognitive stability as key positive outcomes. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard nature of clinical development.
Investor Verification Checklist
- Verify the full text of the press release referenced in Item 8.01 for additional context on the study design.
- Confirm the regulatory status of the CTLA4-Ig and low-dose IL-2 combination for FTD treatment.
- Review the Company's most recent 10-K or 10-Q for current cash position and runway, as this 8-K contains no financial data.
- Assess the statistical significance of the cognitive stability results given the small sample size (n=9).